Synapse - Works

Results (12615)

Characterization of the genetic landscape of low mutation burden malignancies through multi-parallel genomic and immunologic analysis

Meeting Abstract

Trippett, T.; Berger, M.; Narendran, A.; Lyden, D.; Kovalchuk, O.; Bodour, S.; Laquaglia, M.; Ambati, S.; Schultz, N.; Roehrl, M.
European Journal of Cancer (2018)

Fulltext@MSK | Save

Characterization of KDM6A loss in urothelial carcinoma

Meeting Abstract

Wise, H. C.; Hu, W.; Gao, P. S.; Ahmad, A.; McPherson, V. A.; Dason, S.; Pietzak, E. J.; Lyer, G.; Al-Ahmadie, H.; Solit, D. B.
European Journal of Cancer (2018)

Fulltext@MSK | Save

PHF6 mutations are mutually exclusive to TP53 mutations, and define a distinct subgroup of secondary acute myeloid leukemia associated with a primitive stem/progenitor immunophenotype, absent complex karyotype and relatively better outcomes

Meeting Abstract

Xiao, W.; Goldberg, A. D.; Ball, B.; Famulare, C.; Pastore, F.; Tallman, M. S.; Zhang, Y.; Arcila, M. E.; Papaemmanuil, E.; Levine, R. L.; more...
Blood (2018)

Fulltext@MSK | Save

Loss of plasmacytoid dendritic cell differentiation is highly predictive for persistent measurable residual disease and poor outcomes in acute myeloid leukemia

Meeting Abstract

Xiao, W.; Goldberg, A. D.; Famulare, C.; Delvin, S.; Patel, M.; McGovern, E.; Patel, A.; Schulman, J.; Dunbar, A.; Epstein-Peterson, Z. D.; more...
Blood (2018)

Fulltext@MSK | Save

Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents

Meeting Abstract

Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; more...
Blood (2018)

Fulltext@MSK | Save

Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions

Meeting Abstract

Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Pratz, K. W.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; more...
Blood (2018)

Fulltext@MSK | Save

Dysgeusia is associated with higher melphalan pharmacokinetic levels and results in poorer caloric intake and worse symptom burden after autologous stem cell transplantation for multiple myeloma

Meeting Abstract

Scordo, M.; Shah, G. L.; Preston, E. V.; Rodriguez, N.; Lin, A.; Maloy, M.; Mastrogiacomo, B.; Carlow, D.; Schofield, R.; Knezevic, A.; more...
Blood (2018)

Fulltext@MSK | Save

Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial

Meeting Abstract

Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
Blood (2018)

Fulltext@MSK | Save

MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone

Meeting Abstract

Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; more...
Blood (2018)

Fulltext@MSK | Save

The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts

Meeting Abstract

Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; more...
Blood (2018)

Fulltext@MSK | Save